Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Arbutus Biopharma Q2 EPS $(0.10) Beats $(0.13) Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share from
byBill Haddad
August 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What’s Going On With Intel Stock Wednesday?

By Adam Eckert
June 5, 9:19 AM
Intel Corp (NASDAQ:INTC) shares are moving higher Wednesday. Late Tuesday, Intel announced that it entered into a definitive agreement with Apollo-managed funds and affiliates in which the Apollo team will lead an investment of $11 billion to acquire a 49% equity interest from Intel in a joint venture entity related to the company's Fab 34,

INTC